About this trial
This study aims to evaluate the effect of a structured swallowing rehabilitation program on swallowing function, trismus severity, and pain among patients with head and neck tumors, using a randomized controlled trial design. Eighty patients will be randomly allocated into two equal groups: a study group receiving the swallowing rehabilitation program and a control group receiving standard care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Both genders
Aged 20-60 years
Patients receiving chemoradiotherapy
Patients having a history of head and neck cancer
Disqualifiers
Patients who had neurological or psychiatric problems
Patients who had dysphagia for a reason other than cancer
Trial design
Parallel
Treatments tested in this trial
Swallowing Rehabilitation Program
BehavioralA structured program including Mendelsohn maneuver, effortful swallow, Masako technique, tongue strengthening exercises, and jaw range-of-motion and stretching exercises, performed as three sets of ten repetitions twice daily, delivered through orientation, theoretical, and practical sessions.
Treatment groups
Trial outcomes
Primary outcomes
Change in Swallowing Function as Measured by the Eating Assessment Tool-10 (EAT-10)
Swallowing function assessed using the Eating Assessment Tool-10 (EAT-10), a 10-item self-administered questionnaire with total scores ranging from 0 to 40, with higher scores indicating greater swallowing difficulty (0-3 = normal swallowing, ≥4 = possible dysphagia, 10-20 = moderate dysphagia, \>20 = severe dysphagia).
Secondary outcomes
Change in Trismus Severity as Measured by the Gothenburg Trismus Questionnaire 2 (GTQ-2)
Trismus severity assessed using the Gothenburg Trismus Questionnaire 2 (GTQ-2), a 20-item questionnaire with total scores ranging from 24 to 120, with higher scores indicating greater trismus severity (24 = no trismus, 25-57 = mild, 58-89 = moderate, 90-120 = severe trismus).
Other outcomes
Change in Pain Level as Measured by the Numerical Pain Scale (NPS)
Pain level assessed using the Numerical Pain Scale (NPS), ranging from 0 to 10, with higher scores indicating greater pain severity (0 = none, 1-3 = mild, 4-6 = moderate, 7-10 = severe pain).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Delta University for Science and Technology
Lead sponsor
National Cancer Institute, Cairo
Collaborator
Clinical Oncology department. Elmansoura University.
Collaborator